Remdesivir-Associated Sinus Arrest in COVID-19: A Potential Indication for Close Cardiac Monitoring

Remdesivir is an antiviral, nucleoside analog used extensively during the coronavirus-disease 2019 (COVID-19) pandemic with proven efficacy against COVID-19-induced acute respiratory distress syndrome (ARDS). Our case report details the clinical course of a 50-year-old, COVID-19-positive patient who...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-02, Vol.14 (2), p.e22328
Main Authors: Gregory, Grant E, Gregory, Hannah M, Liaqat, Hamza, Ghaly, Mina M, Johnson-Pich, Kristy D
Format: Article
Language:English
Subjects:
Adenosine
Antiviral drugs
Cardiac arrhythmia
Cardiovascular disease
Case reports
Chronic obstructive pulmonary disease
Coronaviruses
COVID-19
Electrocardiography
Heart rate
Internal Medicine
Literature reviews
Medicine
Osteopathic medicine
Patients
Pneumonia
Pulmonology
RNA polymerase
Severe acute respiratory syndrome coronavirus 2
Sinuses
Therapeutics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Remdesivir is an antiviral, nucleoside analog used extensively during the coronavirus-disease 2019 (COVID-19) pandemic with proven efficacy against COVID-19-induced acute respiratory distress syndrome (ARDS). Our case report details the clinical course of a 50-year-old, COVID-19-positive patient who developed sinus arrest after being treated with remdesivir. Within 24 hours of discontinuing remdesivir therapy, the patient's sinus arrest resolved to a normal sinus rhythm. The findings from our case report add to a growing body of evidence on the cardiotoxic profile of remdesivir. Remdesivir's ability to cause bradyarrhythmias, and specifically sinus arrest, should be acknowledged when considering the use of this drug in at-risk patients.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.22328